The question I have is, if we moved from Synthetic CBD to Natural for IHL's current medicines, would we have to repeat our trials? What if the results are below the current results in terms of safety and efficacy - would we stick to synthentic drugs or pivot to naturally produced CBD based on APIRx technology? Or do we proceed in parallel, i.e., IHL continues down its path with synthentic CBD but the APIRx portfolio focusses on naturally produced CBD?
Ann: Incannex to Acquire APIRx Pharmaceuticals, page-94
-
- There are more pages in this discussion • 367 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)